Veradermics (MANE) SEC filings document the formal record behind the company’s late-stage dermatology drug development business. As a clinical-stage biopharmaceutical company focused on VDPHL01 for pattern hair loss, its filings are especially useful for reviewing clinical disclosures, financing activity, equity structure, compensation plans, and quarterly operating updates.
Quarterly reports on Form 10-Q provide detail on items such as marketable securities, stock-based compensation, common and preferred stock matters, pre-funded warrants, and other financial statement notes. Annual reports on Form 10-K, when filed, provide a fuller business and risk-factor record. For Veradermics, these periodic reports are important because the company’s public materials focus on clinical development rather than sales of an approved commercial product.
Form 8-K filings have been used by Veradermics to report material events, including financial results, Regulation FD disclosures, clinical trial data releases, public offering activity, and private placement activity. S-1 registration statements provide information about registered securities, underwriting terms, IPO-related matters, preferred stock conversion, related-party disclosures, and beneficial ownership tables. Form 4 filings, when filed, show insider transactions involving officers, directors, or other reporting persons.
For MANE filing research, key documents include 10-Q quarterly reports, future 10-K annual reports, S-1 registration statements, 8-K material-event reports, and any Form 4 insider transaction reports. Together, these filings show how Veradermics funds development, structures equity, and reports progress for its investigational dermatology program.
Longitude Venture Partners V, L.P. (LVPV) and Longitude 103.8 East, L.P. (L103), investment entities holding Veradermics, Inc. (MANE) common stock, each sold 250,000 shares on November 11, 2026, at $150.38 per share. Each entity reported an aggregate sale price of $37,595,000.
The ownership tables list LVPV as beneficially owning 2,350,399 shares (5.6%) and L103 as beneficially owning 1,803,474 shares (4.3%). Patrick G. Enright, a Veradermics board member, and Juliet Tammenoms Bakker may each be deemed to share voting and dispositive power over 4,153,873 shares (9.8%), held of record by the two entities. The percentages are based on 42,195,472 common shares outstanding as of November 5, 2026.
Veradermics, Inc. (MANE) director Patrick G. Enright reported two indirect sales: Longitude Venture Partners V, L.P. sold 250,000 common shares and Longitude 103.8 East, L.P. sold 250,000 common shares, each at $150.38 per share on November 11, 2026. The partnerships held the shares. Their respective general partners may be deemed to have voting, investment and dispositive power; Enright and Juliet Tammenoms Bakker may each be deemed to share that power and disclaim beneficial ownership except to the extent of their respective pecuniary interests. No Rule 10b5-1 plan is reported.
Two entities holding Veradermics, Inc. (MANE) shares reported indirect sales of common stock on November 11, 2026. Longitude Venture Partners V, L.P. and Longitude 103.8 East, L.P. each sold 250,000 shares at $150.38 per share, for 500,000 shares across the reported transactions. No Rule 10b5-1 plan is reported.
Veradermics, Inc. (MANE) 10% stockholder Longitude Venture Partners V, L.P. gave notice of a proposed sale of 250,000 common shares, with an approximate sale date of November 11, 2026 and an aggregate market value of $37,595,000. An acquisition entry records a cash private placement from the issuer on October 14, 2025. A separate three-month sales table lists Longitude 103.8 East, L.P. as having sold 250,000 common shares on November 11, 2026, for gross proceeds of $37,595,000. Cristiana Oliveira signed the notice.
Veradermics, Inc. (MANE), a clinical-stage biopharmaceutical company, reported a $71.7 million net loss for the nine months ended September 30, 2026, versus $48.1 million in the comparable 2025 period. Net cash used in operating activities was $58.6 million, versus $48.0 million. The company has no approved products and expects operating losses to continue.
Cash, cash equivalents and marketable securities totaled $798.4 million as of September 30, 2026; the company expects these resources to cover obligations for at least 12 months from the date the financial statements are available to be issued. In October, it reported that Phase 3 Study 304 met all primary and secondary endpoints among 536 men. At Month 6, average hair-count increases were 28.6 hairs/cm² once daily and 36.4 hairs/cm² twice daily, versus 6.6 with placebo. The study reported no treatment-related serious adverse events or adverse events of special interest of cardiac origin.
In November, Study 302’s continued-treatment group had Month 12 hair-count increases of 43.9 hairs/cm² BID and 29.7 hairs/cm² QD from baseline. The company expects topline results from female Study 306 in the first half of 2027.
Veradermics, Inc. (MANE) reported third-quarter 2026 results and clinical updates for VDPHL01, its investigational oral treatment for pattern hair loss. Cash, cash equivalents and marketable securities totaled $798.4 million as of September 30, 2026, and the company expects that cash position to fund operations into 2030. Research and development expenses were $16.1 million, compared with $18.1 million a year earlier; general and administrative expenses were $12.7 million, compared with $2.3 million. Net loss was $21.0 million, versus $20.1 million.
In October 2026, Phase 3 Study 304 met all primary and secondary endpoints. Participants receiving VDPHL01 had mean increases in non-vellus target area hair count of 36.4 hairs/cm² (twice daily) and 28.6 hairs/cm² (once daily) at Month 6. In Phase 2/3 Study 302, Month 12 increases in the continued-treatment group were 43.9 hairs/cm² (twice daily) and 29.7 hairs/cm² (once daily); 89.1% and 79.8%, respectively, reported visible hair-coverage improvement. Study 306 enrollment is complete, with topline data expected in the first half of 2027. The company also reported positive topline results from open-label Phase 2 Study 207 in women.
Veradermics, Inc. reported 12-month Part B results from Study ‘302’, a randomized, double-blind, placebo-controlled Phase 2/3 trial of investigational VDPHL01 in men with mild-to-moderate pattern hair loss. The trial enrolled 519 patients, who received 8.5 mg once daily (QD), twice daily (BID), or placebo for six months; placebo participants then crossed to VDPHL01 for the remaining six months.
In the continued-treatment groups, non-vellus hair count increased from baseline by 29.7 hairs/cm² (QD) and 43.9 hairs/cm² (BID) at Month 12. Visible hair-coverage improvement was reported by 79.8% (QD) and 89.1% (BID); 48.4% (QD) and 68.0% (BID) achieved “improved” or “much improved” on the Androgenetic Alopecia Impact Rating Scale (AAIRS). Part B efficacy analyses used observed data available in each group. Veradermics reported no treatment-related serious adverse events, cardiac adverse events of special interest, or new safety signals; no treatment-emergent adverse events led to discontinuation in the continued group from Month 6 to Month 12. VDPHL01 remains investigational, and the company anticipates female pattern hair loss Study ‘306’ data in the first half of 2027.
Veradermics, Inc. (MANE) reported positive topline results from Study ‘304’, a randomized, placebo-controlled Phase 3 trial of VDPHL01 in 536 men with mild-to-moderate pattern hair loss. The study tested 8.5 mg once-daily and twice-daily doses. At Month 6, average non-vellus target-area hair-count increases were 28.6 hairs/cm² with once-daily dosing and 36.4 hairs/cm² twice daily, versus 6.6 hairs/cm² with placebo. The trial met all primary and secondary endpoints, with statistically significant separation from placebo on hair count, patient-reported outcomes and investigator assessment as early as Month 2.
On the Androgenetic Alopecia Impact Rating Scale, 55.7% of once-daily and 68.7% of twice-daily participants reported “improved” or “much improved” hair coverage, versus 15.0% on placebo. Treatment was generally well tolerated through Month 6; no treatment-related serious adverse events or cardiac-origin adverse events of special interest were observed. Hypertrichosis was the only treatment-emergent adverse event above 5% in an active arm, occurring in 2.2% of once-daily and 9.0% of twice-daily participants. VDPHL01 remains investigational. The company anticipated Study ‘302’ Part B topline data in the second half of 2026 and Study ‘306’ topline data in the first half of 2027.
Veradermics, Inc. (MANE) common stock: JPMorgan Chase & Co. reported beneficial ownership of 2,374,502 shares, or 5.6% of the class, as of September 30, 2026. JPMorgan Chase reported sole voting power over 2,231,159 shares and shared voting power over 1 share; its sole and shared dispositive powers were reported for 2,374,185 shares and 1 share, respectively.
Veradermics, Inc (MANE) reported that Chief R&D Officer David Hollander received equity awards on September 1, 2026. He was granted 9,650 shares of Common Stock in the form of restricted stock units and a stock option for 19,300 shares at an exercise price of $97.51 per share, both held directly.
The RSUs vest 25% on each of September 1, 2027, 2028, 2029, and 2030, subject to continued service. The option vests 25% on September 1, 2027, with the remaining shares vesting in equal monthly installments over the following 36 months and expires on September 1, 2036.